ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
US$223,94
arrow_upward
+1,84%(+4,05) 1D
US$226,70
arrow_upward
+1,23% (+2,76)todayPre-market
Closed: 6 ຕ.ລ., 16 ໂມງ 0 ນາທີ 01 ວິນາທີ GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
US$221,02
High
US$229,18
Low
US$217,18
Mkt. cap
29,94 ຕື້
Avg. vol.
1,52 ລ້ານ
Volume
138,00
P/E ratio
38,11
52-wk high
US$495,55
52-wk low
US$197,81
EPS
US$5,88
Beta
0,28
Shares outstanding
133,81 ລ້ານ
No. of employees
2 ພັນ
Open
US$221,02
High
US$229,18
Low
US$217,18
Mkt. cap
29,94 ຕື້
Avg. vol.
1,52 ລ້ານ
Volume
138,00
P/E ratio
38,11
52-wk high
US$495,55
52-wk low
US$197,81
EPS
US$5,88
Beta
0,28
Shares outstanding
133,81 ລ້ານ
No. of employees
2 ພັນ
News stories
From web sources and news partners
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.